Back to search

Article

Early intermittent low-dose sclerostin antibody treatment promotes surface bone formation and reduces bone loss, but also decreases osteocyte apoptosis and mechanotransduction in ovariectomized rats: a pilot study

2024-10-02

Abstract excerpt

Neutralizing sclerostin antibodies (Scl-Ab) mitigate bone loss and promote bone formation to address fracture risk in postmenopausal osteoporosis. Clinically, this treatment is administered monthly for women at high risk of fragility fractures, who are often years into menopause. Preclinical studies have demonstrated that dampening of bone formation occurs with continuous dosing at supraphysiological doses. Osteop...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b3ce8cd4-4e92-5ccd-887d-662508b8e625
DOI
10.1101/2024.10.02.616263
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Early intermittent low-dose sclerostin antibody treatment promotes surface bone formation and reduces bone loss, but also decreases osteocyte apoptosis and mechanotransduction in ovariectomized rats: a pilot studyDOI 10.1101/2024.10.02.616263
Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized ratsSemantic proximity
Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.Semantic proximity
Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in RatsSemantic proximity
Sclerostin antibody treatment rescues the osteopenic bone phenotype of TGFβ inducible early gene-1 knockout female mice.Semantic proximity
SclerostinSemantic proximity
Osteocyte control of bone formation via sclerostin, a novel BMP antagonistSemantic proximity
Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.Semantic proximity
Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss.Semantic proximity
MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosisSemantic proximity
Osteoporosis - a current view of pharmacological prevention and treatment.Semantic proximity
SclerostinSemantic proximity
The Role of Sclerostin in Bone DiseasesSemantic proximity
Select a neighboring publication to make it the new centre.